Evidence map›Paper›PMID 40597851›Full record

ArticleBMC cancer2025

Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.

Hai-Bo Sun, Shao-Kang Feng, Xian-Ben Liu, Wen-Qun Xing, Pei-Nan Chen, Duo Jiang, Yang Liu

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Transthoracic versus Transhiatal Esophagectomy for Esophageal Squamous Cell Carcinoma.JSLS : Journal of the Society of Laparoendoscopic Surgeons
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hai-Bo SunDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou City, Henan Province, China. zlyysunhaibo2122@zzu.edu.cn.
Shao-Kang FengDepartment of Thoracic Surgery, Anyang Tumor Hospital, Anyang City, Henan Province, China.
Xian-Ben LiuDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou City, Henan Province, China.
Wen-Qun XingDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou City, Henan Province, China.
Pei-Nan ChenDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou City, Henan Province, China.
Duo JiangDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou City, Henan Province, China.
Yang LiuDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), No. 127 Dongming Road, Zhengzhou, 450008, Henan Province, China. sunny5799@126.com.

Funding

Health Commission of Henan Province YXKC2020022Wu Jieping Medical Foundation 320.6799.15061
6 · The paper itself

Abstract

backgroundThis study evaluated the association between adjuvant chemotherapy and the survival of cT1b-T2 patients with incidentally discovered positive lymph nodes (cN- but pN+) after esophagectomy for esophageal squamous cell carcinoma. MATERIALS AND

methodsEsophageal cancer patients in whom positive lymph nodes were incidentally discovered after esophagectomy were enrolled in this retrospective cohort study. Patients were divided into the surgery alone and adjuvant chemotherapy groups. Propensity score matching (1:1) was used to minimize baseline differences.

resultsIn total, data from 343 patients who were incidentally discovered to have positive lymph nodes after surgery were analyzed. Each group consisted of 107 patients, with no significant difference in the background information between the two groups. There was also no significant difference in the overall survival (P = 0.227) or disease-free survival (P = 0.210) between the groups in the matched overall study population. Notably, in subgroup analysis, The disease-free survival in the adjuvant chemotherapy group was significantly better than that in the operation group alone for patients with pathological stage T3 (P = 0.023). Multivariate analysis showed that male (ref: female, HR = 1.796, 95% CI, 1.013-3.183, P = 0.045) was a significant independent predictive factor for overall survival.

conclusionAdjuvant chemotherapy may improve survival for patients with cT1b-T2 but pathological T3 stage patients with incidentally discovered node-positive esophageal squamous cell carcinoma.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyLymph NodesAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansIncidental FindingsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingRetrospective StudiesAdjuvant chemotherapyEsophageal squamous cell carcinomaEsophagectomyLymph nodeSurvival

Identifiers

PMID40597851
PMCPMC12211139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.